CAS 1242137-16-1

N-Desmethylenzalutamide

Description:

N-Desmethylenzalutamide is a chemical compound that serves as a metabolite of the anti-androgen drug enzalutamide, which is primarily used in the treatment of prostate cancer. This substance is characterized by its structural modifications that result from the removal of a methylene group from the enzalutamide molecule. N-Desmethylenzalutamide exhibits similar pharmacological properties to its parent compound, including the ability to inhibit androgen receptor signaling, which is crucial in the progression of prostate cancer. The compound is typically studied for its role in drug metabolism and pharmacokinetics, as well as its potential therapeutic implications. In terms of physical properties, N-Desmethylenzalutamide is expected to be a solid at room temperature, with specific solubility characteristics that may influence its bioavailability. Its safety profile and efficacy are subjects of ongoing research, particularly in understanding how it contributes to the overall therapeutic effects of enzalutamide and its potential resistance mechanisms in cancer treatment.

Formula: C₂₀H₁₄F₄N₄O₂S

InChI: InChI=1S/C20H14F4N4O2S/c1-19(2)17(30)27(11-4-3-10(9-25)14(7-11)20(22,23)24)18(31)28(19)12-5-6-13(16(26)29)15(21)8-12/h3-8H,1-2H3,(H2,26,29)

InChI key: InChIKey=JSFOGZGIBIQRPU-UHFFFAOYSA-N

SMILES: S=C1N(C(C)(C)C(=O)N1C2=CC(C(F)(F)F)=C(C#N)C=C2)C3=CC(F)=C(C(N)=O)C=C3

Synonyms:

• N-Desmethylenzalutamide
• Benzamide, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-
• 4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluorobenzamide
• Enzalutamide Impurity R
• CS-1325
• N-DESMETHYL MDV3100;N-DESMETHYL MDV 3100;N-DESMETHYL MDV-3100
• Enzalutamide Impurity 2
• N-desMethyl EnzalutaMide
• Enzalutamide impurity B
• N-desmethyl MDV-3100
• Enzalutamide N-Desmethyl Impurity
• Enzalutamide impurity O
• N-desmethyl MDV3100, N-desmethyl-Enzalutamide
• N-desmethyl MDV 3100
• N-desmethyl MDV3100

N-desmethyl Enzalutamide

CAS: 1242137-16-1

Formula: C₂₀H₁₄F₄N₄O₂S

Purity: 98%

Color and Shape: Solid

Molecular weight: 450.4094

Ref: IN-DA009CDT

N-desmethyl Enzalutamide

CAS: 1242137-16-1

N-desmethyl Enzalutamide

Purity: ≥98%

Molecular weight: 450.41g/mol

Ref: 54-BUP15328

N-Desmethyl Enzalutamide

CAS: 1242137-16-1

Formula: C₂₀H₁₄F₄N₄O₂S

Color and Shape: Off-White Solid

Molecular weight: 450.41

Ref: 4Z-E-068003

N-Desmethyl Enzalutamide-d6

CAS: 1242137-16-1

Formula: C₂₀H₈D₆F₄N₄O₂S

Color and Shape: White To Off-White Solid

Molecular weight: 456.45

Ref: 4Z-E-068002

N-desmethyl Enzalutamide

CAS: 1242137-16-1

N-desmethyl Enzalutamide (N-desmethyl MDV 3100) is the active Enzalutamide metabolite.It is the active metabolite of Enzalutamide.

Formula: C₂₀H₁₄F₄N₄O₂S

Purity: 99.74%

Color and Shape: Solid

Molecular weight: 450.41

Ref: TM-T19450

4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluorobenzamide

CAS: 1242137-16-1

Formula: C₂₀H₁₄F₄N₄O₂S

Color and Shape: Neat

Molecular weight: 450.41

Ref: TR-C987645

N-desmethyl Enzalutamide

CAS: 1242137-16-1

Purity: 98%

Molecular weight: 450.41

Ref: 10-F987630

4-​[3-​[4-​Cyano-​3-​(trifluoromethyl)​phenyl]​-​5,​5-​dimethyl-​4-​oxo-​2-​thioxo-​1-​imidazolidinyl]​-​2-​fluorobenzamide-d6

Controlled Product

CAS: 1242137-16-1

Formula: C₂₀D₆H₈F₄N₄O₂S

Color and Shape: White To Off-White

Molecular weight: 456.446

Ref: TR-C987647

4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluorobenzamide

CAS: 1242137-16-1

Enzalutamide is a potent and selective nonsteroidal antiandrogen that is being studied in the treatment of prostate cancer. Enzalutamide binds competitively to the androgen receptor, preventing it from binding to its natural ligands. The drug has been shown to inhibit prostate cancer in animal models. In clinical studies, enzalutamide significantly decreased serum prostate-specific antigen (PSA) levels and increased tumor response rates in patients with metastatic castration-resistant prostate cancer. The plasma concentration–time curve of enzalutamide was found to be linear over a dose range of 25 to 50 mg per day, with a mean elimination half-life of about 24 h. The pharmacokinetics of enzalutamide are not affected by hepatic impairment or body mass index. Pharmacokinetic parameters were determined using LC-MS/MS methods.br>

Formula: C₂₀H₁₄F₄N₄O₂S

Purity: Min. 95%

Molecular weight: 450.41 g/mol

Ref: 3D-FC102745

N-Desmethyl Enzalutamide Impurity

CAS: 1242137-16-1

Formula: C₂₀H₁₄F₄N₄O₂S

Molecular weight: 450.41

Ref: ST-EA-CP-E16012